Page last updated: 2024-08-21

benzoxazoles and Osteogenic Sarcoma

benzoxazoles has been researched along with Osteogenic Sarcoma in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hirahata, M; Okada, F; Osaki, M; Sasaki, R; Tsuge, M	1
de Stanchina, E; Patwardhan, PP; Schwartz, GK; Slotkin, EK; Tap, WD; Vasudeva, SD	1

Other Studies

2 other study(ies) available for benzoxazoles and Osteogenic Sarcoma

Article	Year
SK-216, a Novel Inhibitor of Plasminogen Activator Inhibitor-1, Suppresses Lung Metastasis of Human Osteosarcoma. International journal of molecular sciences, 2018, Mar-05, Volume: 19, Issue:3 Topics: Animals; Antineoplastic Agents; Benzoxazoles; Cell Line, Tumor; Dicarboxylic Acids; Lung Neoplasms; Male; Matrix Metalloproteinase 13; Mice; Mice, Nude; Osteosarcoma; Plasminogen Activator Inhibitor 1	2018
MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma. Molecular cancer therapeutics, 2015, Volume: 14, Issue:2 Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Benzoxazoles; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Down-Regulation; Female; Humans; Inhibitory Concentration 50; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice, Nude; Multiprotein Complexes; Osteosarcoma; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Sirolimus; Substrate Specificity; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2015

Article

Year

SK-216, a Novel Inhibitor of Plasminogen Activator Inhibitor-1, Suppresses Lung Metastasis of Human Osteosarcoma.

International journal of molecular sciences, 2018, Mar-05, Volume: 19, Issue:3

Topics: Animals; Antineoplastic Agents; Benzoxazoles; Cell Line, Tumor; Dicarboxylic Acids; Lung Neoplasms; Male; Matrix Metalloproteinase 13; Mice; Mice, Nude; Osteosarcoma; Plasminogen Activator Inhibitor 1

2018

MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.

Molecular cancer therapeutics, 2015, Volume: 14, Issue:2

Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Benzoxazoles; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Down-Regulation; Female; Humans; Inhibitory Concentration 50; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice, Nude; Multiprotein Complexes; Osteosarcoma; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Sirolimus; Substrate Specificity; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2015